Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease-Reference-Cited by-同舟云学术

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Published:2024-07-18 Issue:3 Volume:391 Page:213-223
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Peyrin-Biroulet Laurent¹,Chapman J. Casey¹,Colombel Jean-Frederic¹,Caprioli Flavio¹,D’Haens Geert¹,Ferrante Marc¹,Schreiber Stefan¹,Atreya Raja¹,Danese Silvio¹,Lindsay James O.¹,Bossuyt Peter¹,Siegmund Britta¹,Irving Peter M.¹,Panaccione Remo¹,Cao Qian¹,Neimark Ezequiel¹,Wallace Kori¹,Anschutz Toni¹,Kligys Kristina¹,Duan W. Rachel¹,Pivorunas Valerie¹,Huang Xiu¹,Berg Sofie¹,Shu Lei¹,Dubinsky Marla¹

Affiliation:

1. From the Department of Gastroenterology, INFINY Institute, INSERM NGERE, Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, France (L.P.-B.); the Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal (L.P.-B.), and the Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB (R.P.) — both in Canada; the Crohn’s and Colitis Center at the Baton Rouge General and the GI Alliance, Baton Rouge,...

Funder

AbbVie

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2314585

Reference38 articles.

1. Crohn’s disease

2. Head-to-head trials in inflammatory bowel disease: past, present and future

3. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?

4. Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn’s disease treated with anti-tumor necrosis factor antibodies

5. Sochal M Krzywdzińska M Gabryelska A Talar-Wojnarowska R Białasiewicz P Małecka-Panas E. A simple index to predict the efficiency of adalimumab treatment in Crohn disease with a limited duration of therapy. Pol Arch Intern Med 2020;130:910-912 (https://www.mp.pl/paim/issue/article/15507).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-21 and Interleukin-23 levels in familial Mediterranean Fever before and after treatment: the role of cytokines in disease pathogenesis;Scientific Reports;2024-09-12

2. Evaluating Efficacy of Vedolizumab, Ustekinumab, and Golimumab in the Management of Inflammatory Bowel Disease and the Combined Role of Nutritional Therapy with Biologics: A Review;Biologics;2024-08-30

3. Risankizumab versus ustekinumab for Crohn’s disease: a phase IIIb study;Nature Reviews Gastroenterology & Hepatology;2024-08-05

4. Interleukin-23 p19 and Interleukin-12 p40, Head-to-Head, against Gut Inflammation;New England Journal of Medicine;2024-07-18